Serina Therapeutics ownership filing reports that Sio Capital Management, LLC beneficially owned 1,000,000 shares of common stock as of March 31, 2026, representing 6.71% of the class. The filing cites 14,898,617 shares outstanding as of April 20, 2026 per the issuer's DEF 14A.
The statement explains Sio exercises shared voting and dispositive power over the shares through advisory relationships; footnotes describe related GP and control disclosures by Michael Castor and include an ownership disclaimer. The filing is signed by the Chief Compliance Officer.
Positive
None.
Negative
None.
Insights
Sio holds a mid‑single‑digit stake reported under Schedule 13G.
Sio Capital Management reports beneficial ownership of 1,000,000 shares with shared voting and dispositive power as of March 31, 2026. The filing references 14,898,617 shares outstanding as of April 20, 2026, yielding a 6.71% stake.
The disclosure follows passive/investment‑manager reporting norms; footnotes note oversight by an affiliated GP and control links to Michael Castor while disclaiming beneficial ownership by the GP. Subsequent filings may update percentages if outstanding share counts change.
Key Figures
Beneficially owned:1,000,000 sharesPercent of class:6.71%Shares outstanding:14,898,617 shares+1 more
4 metrics
Beneficially owned1,000,000 sharesAmount beneficially owned as of March 31, 2026
Percent of class6.71%Percent of common stock based on outstanding shares cited
Shares outstanding14,898,617 sharesShares outstanding as of April 20, 2026 per issuer DEF 14A
CUSIP81751A108Serina Therapeutics Common Stock CUSIP
"As of March 31, 2026, Sio Capital Management, LLC beneficially owned 1,000,000 shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting powerregulatory
"Shared Voting Power 1,000,000.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Schedule 13Gregulatory
"This Statement is filed on behalf of Sio Capital Management, LLC"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
SERINA THERAPEUTICS, INC.
(Name of Issuer)
Common Stock, par value, $0.0001 per share
(Title of Class of Securities)
81751A108
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
81751A108
1
Names of Reporting Persons
Sio Capital Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,000,000.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,000,000.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,000,000.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.71 %
12
Type of Reporting Person (See Instructions)
IA
Comment for Type of Reporting Person: 1 As of March 31, 2026, Sio Capital Management, LLC beneficially owned 1,000,000 shares of Common Stock with shared voting power and shared dispositive power.
2 Based upon 14,898,617 Common Shares outstanding as of April 20, 2026, as disclosed by the Issuer's DEF 14A on April 27, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
SERINA THERAPEUTICS, INC.
(b)
Address of issuer's principal executive offices:
601 Genome Way, Suite 2001, Huntsville, AL 35806
Item 2.
(a)
Name of person filing:
This Statement is filed on behalf of Sio Capital Management, LLC (the "Reporting Person" or "Sio")
Sio is a registered investment adviser to certain affiliated funds that directly hold the shares of Common Stock to which this statement relates for the benefit of their respective investors, and in such capacity Sio has voting and dispositive power over such shares.
(b)
Address or principal business office or, if none, residence:
600 Third Avenue, 2nd Floor
New York, New York 10016
(c)
Citizenship:
Sio is a Delaware limited liability company.
(d)
Title of class of securities:
Common Stock, par value, $0.0001 per share
(e)
CUSIP Number(s):
81751A108
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
1,000,000
(b)
Percent of class:
6.71 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
0
(ii) Shared power to vote or to direct the vote:
1,000,000 - Refer to footnote 3
3 Sio and Sio GP, LLC (the "GP") act as investment advisor and general partner, respectively, to various clients that are the record owners of the Common Stock reported on this Schedule 13G. Because Sio's investment discretion with respect to such clients is subject to oversight by the GP, the GP may be deemed to be the beneficial owner of the Common Stock of the Issuer owned by such clients. In addition, both Sio and the GP are controlled by Michael Castor. As such, he may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of Common Stock reported on this Schedule 13G. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.
(iii) Sole power to dispose or to direct the disposition of:
0
(iv) Shared power to dispose or to direct the disposition of:
1,000,000 - Refer to footnote 3
3 Sio and Sio GP, LLC (the "GP") act as investment advisor and general partner, respectively, to various clients that are the record owners of the Common Stock reported on this Schedule 13G. Because Sio's investment discretion with respect to such clients is subject to oversight by the GP, the GP may be deemed to be the beneficial owner of the Common Stock of the Issuer owned by such clients. In addition, both Sio and the GP are controlled by Michael Castor. As such, he may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of Common Stock reported on this Schedule 13G. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What stake does Sio Capital hold in Serina Therapeutics (SER)?
Sio Capital reports beneficial ownership of 1,000,000 shares, equal to 6.71% of Serina Therapeutics common stock. This percentage is calculated using 14,898,617 shares outstanding cited in the filing.
As of which date is Sio Capital's Serina (SER) ownership reported?
The ownership amount is reported as of March 31, 2026. The filing also cites the issuer's outstanding share count as of April 20, 2026 for percentage calculation.
Does Sio Capital have sole voting power over SER shares?
No. The filing states Sio has shared voting power and shared dispositive power over 1,000,000 shares; sole voting and dispositive power are listed as 0.
Why does the filing mention Sio GP and Michael Castor?
Footnotes explain Sio and Sio GP act as advisor and general partner to record owners, and Michael Castor controls those entities; the footnote also expressly disclaims admission of beneficial ownership by the GP or Mr. Castor.
